Dynamic Technology Lab Private LTD Editas Medicine, Inc. Transaction History

Dynamic Technology Lab Private LTD

  • $550 Million
  • Q3 2025

A detailed history of Dynamic Technology Lab Private LTD transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Dynamic Technology Lab Private LTD holds 72,840 shares of EDIT stock, worth $189,384. This represents 0.05% of its overall portfolio holdings.

Number of Shares
72,840
Holding current value
$189,384
% of portfolio
0.05%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025
BUY
$2.2 - $3.52 $160,248 - $256,396
72,840 New
72,840 $252,000
Q3 2024

Nov 12, 2024
BUY
$3.39 - $5.96 $238,683 - $419,631
70,408 New
70,408 $240,000
Q1 2024

May 14, 2024
BUY
$7.03 - $11.07 $317,439 - $499,865
45,155 New
45,155 $335,000
Q3 2023

Nov 14, 2023
BUY
$6.92 - $9.31 $309,151 - $415,924
44,675 New
44,675 $348,000
Q1 2023

May 12, 2023
BUY
$7.03 - $11.53 $206,780 - $339,143
29,414 New
29,414 $213,000
Q3 2022

Nov 14, 2022
BUY
$12.16 - $19.42 $339,665 - $542,458
27,933 Added 118.85%
51,435 $630,000
Q2 2022

Aug 12, 2022
BUY
$9.99 - $21.35 $234,784 - $501,767
23,502 New
23,502 $278,000
Q2 2020

Aug 14, 2020
SELL
$18.5 - $34.34 $215,118 - $399,305
-11,628 Closed
0 $0
Q1 2020

May 13, 2020
BUY
$14.88 - $32.78 $173,024 - $381,165
11,628 New
11,628 $231,000
Q3 2017

Nov 08, 2017
SELL
$15.81 - $24.01 $388,815 - $590,477
-24,593 Closed
0 $0
Q2 2017

Aug 17, 2017
BUY
N/A
24,593
24,593 $413,000

Others Institutions Holding EDIT

# of Institutions
226
Shares Held
46.2M
Call Options Held
841K
Put Options Held
304K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $179M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email